AZNAstraZenecaRunning, no new patients
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,174 (final count)
- Started
- Nov 28, 2022
- Main results expected
- Sep 1, 2027
- Fully finished
- Feb 28, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICT
Measured over: From randomisation to date of the event, up to 57 months from first subject in
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05629585 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC